Intra-Cellular Therapies Inc (OQ:ITCI)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 430 East 29th Street, Suite 900
Tel: N/A
IR: See website
Key People
Sharon Mates
Chairman of the Board, Chief Executive Officer
Michael I. Halstead
Lawrence J. Hineline
Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary
Suresh K. Durgam
Executive Vice President, Chief Medical Officer
Mark Neumann
Executive Vice President, Chief Commercial Officer
Business Overview
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company's product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.
Financial Overview
For the three months ended 31 March 2024, Intra-Cellular Therapies Inc revenues increased 52% to $144.9M. Net loss decreased 65% to $15.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest income increase of 39% to $6.1M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.46 to -$0.16.
Employees: 610 as of Feb 1, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $7,493M as of Mar 31, 2024
Annual revenue (TTM): $513.93M as of Mar 31, 2024
EBITDA (TTM): -$131.42M as of Mar 31, 2024
Net annual income (TTM): -$110.87M as of Mar 31, 2024
Free cash flow (TTM): -$98.52M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 105,574,855 as of May 3, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.